On June 2, Core Scientific rose 5.78% in regular trading, trading at $30.3/share, with trading volume of approximately $77.67 million. The stock has broken through prior key price levels, reflecting sustained upward momentum.

On the news front, investment bank B.Riley recently raised the company's target price from $30 to $33 while maintaining a buy rating. The analyst consensus target price stands at $30.12, with the current share price now approaching that level after a multi-session recovery. Additionally, the company has recently filed multiple Form 4 and Schedule 13G/A documents, indicating ongoing changes in institutional investor holdings. The market interprets these filings as positive signals of capital inflows, which have jointly propelled the stock's continued advance.

Within the Application Software sector, compute-related names showed relative strength, with IREN Ltd rising 4.44%, providing sector linkage support for Core Scientific. Meanwhile, other sector constituents diverged, with Palantir down 4.1%, Strategy down 6.92%, Salesforce down 3.93%, and Intuit down 8.06%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)